louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00680238: Pregnancy/Implantation Rates Using a Day 3 Score Versus Graduated Embryo Score Plus a Biochemical Marker (sHLA-G)
Official title: Pregnancy and Implantation Rates When Embryos Are Selected Based on a Single Day 3 Score (Day 3)vs Graduated Embryo Score(GES) Plus Soluble Human Leukocyte Antigen-G Expression.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infertility
Keywords: Pregnancy
implantation
miscarriage
sHLA-G
Lead sponsor: University of Stellenbosch
Sponsor class: OTHER
First posted: 2008-05-20
Enrollment: 214
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Objective: To compare pregnancy rates and implantation rates when embryos are selected based on a single Day 3 (D.3) score vs. a GES score plus sHLA-G expression.

Detailed description: Comparing pregnancy rates and implantation rates when embryos are selected using the most common criteria for embryo selection on day 3 - the morphology-(number of blastomere, their shape and size and the percentage of fragmentation)vs a graduated embryo score accumulated over 72 hours and the expression of sHLA-G at 44-46 hours post fertilization.

Eligibility criteria: Inclusion Criteria:

* Self paying ART patients

Exclusion Criteria:

* Abnormal uterus
* Specific Immunologic factors

Primary outcomes:
measure: Pregnancy and implantation rates
timeFrame: 12 weeks
Secondary outcomes:
measure: Miscarriage rates
timeFrame: 9 months
measure: Miscarriage rates
timeFrame: 9-11 day until βhCG
Other outcomes:
Locations:
Study officials:
affiliation: University of Stellenbosch
name: Thinus Kruger, M.D. PhD.
role: STUDY_DIRECTOR
References:
Clinical trial NCT00004638: Immunologic Aspects of the Pathogenesis of Chronic Sinusitis in Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sinusitis
Keywords: chronic sinusitis
Lead sponsor: National Center for Research Resources (NCRR)
Sponsor class: NIH
First posted: 2000-02-24
Sex: ALL
Minimum age (years): 0
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Primary purpose: DIAGNOSTIC

Brief summary: Chronic sinusitis is a common pediatric disease; it ranks among the top five infectious diseases of the upper respiratory tract. Its treatment is limited and may be due largely in part to a lack of understanding of its cause. The investigators have preliminary data to support the notion that pediatric chronic sinusitis is a distinct disease, different from acute sinusitis and adult chronic sinusitis. We are proposing to perform pathogenesis studies in children with chronic sinusitis. Specifically, we wish to elucidate the microbiologic features and immunologic factors involved in the formation of this disease. The study plan calls for microbiologic (bacterial, viral, and fungal) and immunologic (inflammatory mediators and leukocyte populations) data to be evaluated through a maxillary sinus washing and mucosal biopsies. Four populations will be studied and they are: 10 children with chronic sinusitis, 5 children with acute sinusitis (positive control), 5 children without sinusitis (negative control) and 5 adults with chronic sinusitis (positive secondary control).


Eligibility criteria: Inclusion Criteria:

* chronic sinusitis confirmed by imaging study for greater than 12 weeks subjects have failed medical therapy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Denver
country: United States
facility: The Children's Hospital
state: Colorado
Study officials:
References:
Clinical trial NCT04422938: Mechanical Versus Manual Cardiopulmonary Resuscitation
Official title: Mechanical Versus Manual Chest Compression: A Retrospective Study in In-hospital Cardiac Arrest
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiac Arrest
Resuscitation
Keywords: Cardiopulmonary Resuscitation
Chest compression
In-hospital
Mechanical
Manuel
Lead sponsor: Ankara City Hospital Bilkent
Sponsor class: OTHER
Collaborators: name: Ankara Training and Research Hospital
First posted: 2020-06-09
Enrollment: 303
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Cases with cardiac arrest in-hospital environment (in emergency department) and whose had manual or mechanical cardiopulmonary resuscitation in emergency department included in the study; data were collected hospital management information system and analyzed retropectively.

Brief summary: In this study, the investigators compared mechanical and manual chest compressions in in-hospital cardiac arrest cases.

Detailed description: In this study, the investigators analyzed cardiopulmonary resuscitations performed over a 2-year period in an emergency department of a training and research hospital and compared success of manual and mechanical chest compressions in terms of return of spontaneous circulation, 30-day survival, and hospital discharge. Investigators present the study as an in-hospital cardiac arrest study; however, all of the resuscitation performed in the cases included in the study were performed in the emergency department.

Eligibility criteria: Inclusion Criteria:

Over 18 age Cardiac arrest cases In-hospital cardiac arrest cases Resuscitations performed in emergency department

Exclusion Criteria:

\<18 age

Primary outcomes:
measure: Mortality rate on the 30th day
timeFrame: 30 days
measure: Rate of the return of spontaneous circulation
timeFrame: 5 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ankara Yıldırım Beyazıt University, School of Medicine, Department of Emergency Medicine
state: Çankaya
Study officials:
References:
citation: Couper K, Yeung J, Nicholson T, Quinn T, Lall R, Perkins GD. Mechanical chest compression devices at in-hospital cardiac arrest: A systematic review and meta-analysis. Resuscitation. 2016 Jun;103:24-31. doi: 10.1016/j.resuscitation.2016.03.004. Epub 2016 Mar 11.
citation: Couper K, Quinn T, Lall R, Devrell A, Orriss B, Seers K, Yeung J, Perkins GD; COMPRESS-RCT collaborators. Mechanical versus manual chest compressions in the treatment of in-hospital cardiac arrest patients in a non-shockable rhythm: a randomised controlled feasibility trial (COMPRESS-RCT). Scand J Trauma Resusc Emerg Med. 2018 Aug 30;26(1):70. doi: 10.1186/s13049-018-0538-6.
Clinical trial NCT01470638: A Study of Flt3-Ligand Levels in Sjögrens Syndrome
Official title: Analyzes of Cerebrospinal Fluid in Autoimmune Systemic Diseases
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sjogrens Syndrome
Keywords: Flt3-L
CSF
Lead sponsor: Göteborg University
Sponsor class: OTHER
First posted: 2011-11-11
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The rheumatology clinic at Sahlgrenska University hospital, Gothenburg, Sweden

Brief summary: The study aims to correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome.

Detailed description: The study aims to correlate levels of Flt3-ligand in CSF and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome.

Eligibility criteria: Inclusion Criteria:

* fulfill the ACR-criteria for primary Sjogrens syndrome,
* age above 18 years old

Exclusion Criteria:

* other CNS-disease

Primary outcomes:
measure: Correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome
timeFrame: June 2009 - June 2015
Secondary outcomes:
Other outcomes:
Locations:
city: Gothenburg
country: Sweden
facility: Dept of Rheumatology, Sahlgrenska University Hospital
Study officials:
References:
Clinical trial NCT00885638: Effects of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Hormonal Responses to Macronutrient Ingestion
Official title: Study of the Effect of Sitagliptin on the Hormonal Responses to Macronutrient Ingestion in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Healthy
Type 2 Diabetes
Keywords: GLP-1
Insulin secretion
Macronutrients
Lead sponsor: Lund University
Sponsor class: OTHER
First posted: 2009-04-22
Enrollment: 12
Sex: MALE
Minimum age (years): 20
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The regulation by DPP-4 inhibition after ingested of different individual macronutrients is not known. Therefore, this study examines the influence of ingestion of fat, protein, glucose or mixed meal on the concentrations of incretin hormones and insulin secretion with or without concomitant administration of a DPP-4 inhibitor (sitagliptin).

Detailed description: Meal ingestion releases gut hormones which stimulate insulin secretion. A most important gut hormone is the incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 is rapidly degraded and inactivated after its release by the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of DPP-4 therefore increases the concentration of active GLP-1 after meal ingestion, which augments insulin secretion. How this process is regulated after ingested of different individual macronutrients is not known. Therefore, this study examines the influence of ingestion of fat, protein, glucose or mixed meal on the concentrations of incretin hormones and insulin secretion with or without concomitant administration of a DPP-4 inhibitor (sitagliptin).

Eligibility criteria: Inclusion Criteria:

* Healthy men
* Age 20-30 years
* BMI 20-30 kg/m2

Exclusion Criteria:

* Any disease
* Any medication

Primary outcomes:
measure: Glucagon-like Peptide-1 Secretion After Meal Ingestion
timeFrame: 300 min
Secondary outcomes:
measure: Insulin Secretion After Ingestion of Meal
timeFrame: 300 min
Other outcomes:
Locations:
city: Lund
country: Sweden
facility: Department of Clinical Sciences Lund, Lund University
Study officials:
affiliation: Lund University
name: Bo Ahrén, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Carr RD, Larsen MO, Winzell MS, Jelic K, Lindgren O, Deacon CF, Ahren B. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Am J Physiol Endocrinol Metab. 2008 Oct;295(4):E779-84. doi: 10.1152/ajpendo.90233.2008. Epub 2008 Jul 8.
citation: Ohlsson L, Alsalim W, Carr RD, Tura A, Pacini G, Mari A, Ahren B. Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects. Diabetes Obes Metab. 2013 Jun;15(6):531-7. doi: 10.1111/dom.12062. Epub 2013 Feb 7.
Clinical trial NCT02667938: A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules
Official title: A Multicenter, Randomized, Double-blind, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Benign Prostatic Hyperplasia
Lead sponsor: Hanmi Pharmaceutical Company Limited
Sponsor class: INDUSTRY
First posted: 2016-01-29
Enrollment: 510
Sex: MALE
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main objective of this study is to evaluate efficacy and safety of HCP1301 capsule in patients with Benign Prostatic Hyperplasia and Erectile Dysfunction

Detailed description: A multicenter, randomized, double-blind, phase 3 clinical trial to evaluate the efficacy and safety of HCP1303 capsule

Eligibility criteria: Inclusion Criteria:

* At Visit 1

  1. ≥50 age
  2. BPH(Benign Prostatic Hyperplasia) + Total IPSS(International Prostate Symptom Score) ≥ 13
  3. Abnormal Erectile function ≥ at least 3months based on screening date
* At Visit 2 1. Total IPSS ≥ 13

Exclusion Criteria:

1. History of hypersensitivity to Tamsulosin or Tadalafil
2. History of allergy for Sulfonamide
3. PSA (Prostate Specific Antigen) ≥4ng/mL

Primary outcomes:
measure: Change of Total IPSS (International Prostate Symptom Score)
timeFrame: baseline and 12 weeks
Secondary outcomes:
measure: Change of Total IPSS
timeFrame: baseline and 4weeks, 8sweeks
Other outcomes:
Locations:
Study officials:
affiliation: Catholic University of Seoul St.Mary's Hospital
name: Se Woong Kim, M.D.,Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03211338: Inflammation and Cell Maturation in Preterm Delivery Placentas - in Vitro and in Vivo Effect of Progesterone
Official title: Inflammation and Cell Maturation in Preterm Delivery Placentas - in Vitro and in Vivo Effect of Progesterone
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obstetric Labor, Premature
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2017-07-07
Enrollment: 115
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The aim of this study is to investigate the In Vitro and In Vivo effect of progesterone on immature myeloid cells (IMC), inflammation characteristics and maturation into dendritic cells (DC).


Eligibility criteria: Inclusion Criteria:

* Placentas from term and preterm deliveries
* Singleton pregnancy
* Consent to participate

Exclusion Criteria:

* Pregnancies with obstetric complications
* Multiple gestation
* Maternal illness or fetal malformation known pre-delivery

Primary outcomes:
measure: Inflammation characteristic effects of progesterone on preterm and term placentas
timeFrame: One year
measure: Maturation effects of progesterone on preterm and term placentas
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
city: H̱adera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
affiliation: Hillel Yaffe Medical Center
name: Rinat Gabbay-Benziv, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05139238: Postpartum Hypertension Study
Official title: Oral Nifedipine Versus Intravenous Labetalol for Postpartum (PP) Hypertensive Emergency: A Randomized Clinical Trial (RCT)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Postpartum Pregnancy-Induced Hypertension
Postpartum Preeclampsia
Pregnancy-Induced Hypertension in Postpartum
Hypertensive Emergency
Keywords: Hypertension
Hypertensive Emergency
Postpartum
Preeclampsia
Lead sponsor: Columbia University
Sponsor class: OTHER
First posted: 2021-12-01
Enrollment: 104
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess which blood pressure medication (intravenous labetalol or oral nifedipine) works better in treating severely elevated blood pressure in women who have just delivered a baby.

Detailed description: Hypertensive emergencies cause significant maternal morbidity and mortality in the postpartum period. In order to reduced these risks, the recommendation is to treat women with severe range blood pressure with either intravenous labetalol or oral nifedipine; it is unclear which medication is superior. The objective of this study is to prospectively enroll women who have hypertensive emergencies in the postpartum period; women will be randomized in a 1:1 fashion and treated with one of the two antihypertensives to see which one works better.

Eligibility criteria: Inclusion criteria

* Patients admitted to labor and delivery (L\&D) with blood pressure (BP) in severe range, defined as a systolic ≥160 mm Hg and/or diastolic ≥110 mm Hg
* Postpartum, immediately to 6 weeks postpartum
* With a prior diagnosis of chronic hypertension (not on medication) or hypertensive disorder of pregnancy

Exclusion criteria

* They may not have previously had exposure to either study medication within the previous 24-hour period.
* Patients with a known atrial-ventricular heart block or moderate to severe bronchial asthma will be excluded, or other contraindication to receiving either study medication

Primary outcomes:
measure: Average Time to Initial Blood Pressure Control (minutes)
timeFrame: Up to 48 hours
Secondary outcomes:
measure: Average Number of Recurrence of Severe Blood Pressure
timeFrame: Up to 48 hours
measure: Total Number of Participants Who Need for Second Antihypertensive Agent
timeFrame: Up to 48 hours
Other outcomes:
Locations:
city: New York
country: United States
facility: Columbia University Irving Medical Center
state: New York
Study officials:
affiliation: Columbia University
name: Whitney A. Booker, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05041738: Comparative Evaluation of the Efficacy of Intraoral Cryotherapy Versus Intracanal Cryotherapy on Postoperative Pain
Official title: Comparative Evaluation of the Efficacy of Intraoral Cryotherapy Versus Intracanal Cryotherapy on Postoperative Pain in Lower Molar Teeth With Irreversible Pulpitis and Symptomatic Apical Periodontitis Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Postoperative Pain
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2021-09-13
Enrollment: 68
Sex: ALL
Minimum age (years): 20
Maximum age (years): 20
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to clinically compare the efficacy of intraoral cryotherapy versus intracanal cryotherapy after single visit root canal therapy in lower molars with irreversible pulpitis and symptomatic apical periodontitis


Eligibility criteria: Inclusion Criteria:

Systemically healthy patient (ASA I or II).

Mandibular first molar teeth with:

* Preoperative sharp pain and symptomatic apical periodontitis
* Absence or slight widening in the periodontal ligament (PDL).
* Vital response of pulp tissue to cold pulp tester (ethyl chloride spray) .
* Positive response to percussion test

Exclusion Criteria:

1. Medically compromised patients.
2. Pregnant women.
3. Patients reporting bruxism or clenching.
4. Patients allergic to ciprofloxacin or metronidazole.
5. Teeth associated with acute periapical abscess and/or swelling.
6. Greater than grade I mobility or pocket depth greater than 5mm.
7. Size of periapical radiolucency is greater than 8 mm.
8. No restorability: Hopeless tooth.
9. Immature teeth.
10. Radiographic evidence of external or internal root resorption vertical root fracture, perforation, calcification.

Primary outcomes:
measure: Postoperative pain assessed using Visual Analogue scale
timeFrame: 6 hours post treatment
measure: Postoperative pain assessed using Visual Analogue scale
timeFrame: 12 hours post treatment
measure: Postoperative pain assessed using Visual Analogue scale
timeFrame: 24 hours post treatment
Secondary outcomes:
measure: Postoperative pain assessed using Visual Analogue scale
timeFrame: 48 hours post treatment
measure: Postoperative pain assessed using Visual Analogue scale
timeFrame: 72 hours post treatment
Other outcomes:
measure: Number of analgesics taken by the patient
timeFrame: Up to 72 hours
Locations:
Study officials:
References:
citation: Fayyad DM, Abdelsalam N, Hashem N. Cryotherapy: A New Paradigm of Treatment in Endodontics. J Endod. 2020 Jul;46(7):936-942. doi: 10.1016/j.joen.2020.03.019. Epub 2020 May 6.
citation: Gundogdu EC, Arslan H. Effects of Various Cryotherapy Applications on Postoperative Pain in Molar Teeth with Symptomatic Apical Periodontitis: A Preliminary Randomized Prospective Clinical Trial. J Endod. 2018 Mar;44(3):349-354. doi: 10.1016/j.joen.2017.11.002. Epub 2018 Feb 3.
Clinical trial NCT04410679: Treatment of Internal Inflammatory Root Resorption Using Injectable PRF Revascularization Technque
Official title: Treatment of Internal Inflammatory Root Resorption Using Injectable PRF Revascularization Technique: A Clinical Study With Cone Beam Computed Tomography Evaluation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Root Resorption
Keywords: Pulp revascularization
injectable Platelet rich fibrin
i-PRF
root resorption
CBCT
Lead sponsor: Fayoum University
Sponsor class: OTHER
First posted: 2020-06-01
Enrollment: 10
Sex: ALL
Minimum age (years): 13
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Currently Endodontics looks forward for regeneration rather than repair. Regenerative endodontic therapy was limited to pulp revascularization of necrotic pulp in immature teeth , followed by mature teeth. Recently pulp revascularization technique by induction of blood clot was applied in the treatment of inflammatory root resorption. So far, no clinical study for management of teeth with inflammatory internal root resorption by using injectable PRF revascularization has been described in the literature. Thus, this is the first clinical attempt to manage inflammatory root resorption in necrotic incisor teeth using injectable PRF regenerative approach.

Detailed description: 13 teeth in a total of 10 patients with inflammatory root resorption will be treated using revascualrization technique, iPRF will be prepared and unjected in the canal after previous canal disinfection with calcium hydroxide for 2-4 weeks. cBCT will be taken preoperative and 12 month follow up period, also clinical and radiographic follow uo will be considered every 3 months for 1 year.

Eligibility criteria: Inclusion Criteria:

* patients 13-30 years old
* no sex predilection
* medically free
* Suffering from internal inflammatory root resorption in permanent anterior mature teeth
* associated with or without periapical radiolucency
* no or grade I tooth mobility, and a pocket depth \<3 mm

Exclusion Criteria:

* old age
* Medically medically compromised patients

Primary outcomes:
measure: change in volumetric size of internal root resorption lesions
timeFrame: 12 months
Secondary outcomes:
measure: change in volumetric size of periapical lesions
timeFrame: 12 months
Other outcomes:
Locations:
city: Fayoum
country: Egypt
facility: Faculty of dentistry Fayoum University
Study officials:
affiliation: Faculty of dentistry, Fayoum University
name: Mohamed Nageh, Lecturer
role: PRINCIPAL_INVESTIGATOR
References: